Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

<p>Supplemental Figures 1 - 5</p>

保存先:

書誌詳細
第一著者:	Timothy P. DiPeri (16384177) (author)
その他の著者:	Kurt W. Evans (16384180) (author), Maria Gabriela Raso (15107821) (author), Ming Zhao (16384183) (author), Yasmeen Q. Rizvi (16384186) (author), Xiaofeng Zheng (16384189) (author), Bailiang Wang (16384192) (author), Bryce P. Kirby (16384195) (author), Kathleen Kong (16384198) (author), Michael Kahle (16384201) (author), Timothy A. Yap (15028749) (author), Ecaterina E. Dumbrava (16384204) (author), Jaffer A. Ajani (11016306) (author), Siqing Fu (15047712) (author), Khandan Keyomarsi (14958560) (author), Funda Meric-Bernstam (10258780) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology DNA Damage and Repair Gastrointestinal Cancers Preclinical Models Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
著者:: Sheheryar Kabraji (15050565)
出版事項: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
著者:: Javier Pascual (15018176)
出版事項: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
著者:: Javier Pascual (15018176)
出版事項: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
著者:: Javier Pascual (15018176)
出版事項: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
著者:: Javier Pascual (15018176)
出版事項: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
著者:: Javier Pascual (15018176)
出版事項: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
著者:: Gia-Buu Tran (16437051)
出版事項: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
著者:: Vishwajith Sridharan (15047154)
出版事項: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
著者:: Alyssa C. Flint (16676029)
出版事項: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
著者:: Ulka N. Vaishampayan (15051039)
出版事項: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
著者:: Sebastian Johannes Schober (14971891)
出版事項: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
著者:: Carlotta Antoniotti (15352506)
出版事項: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
著者:: Santiago Duro-Sánchez (14959182)
出版事項: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
著者:: Alyssa C. Flint (16676029)
出版事項: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
著者:: Ulka N. Vaishampayan (15051039)
出版事項: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
著者:: Ulka N. Vaishampayan (15051039)
出版事項: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
著者:: Jennifer L. Cotton (17315204)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ria69pbkqtcc68m19uhcvjq8jf